Baikal Skullcap

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph. Scutellaria baicalensis was not part of the German or European phytotherapy tradition at the time of Commission E evaluations (1978-1994). The herb is essentially unknown in European traditional medicine.

ESCOP

• No ESCOP monograph for Scutellaria baicalensis.

EMA/HMPC

• No HMPC assessment or monograph initiated. Scutellaria baicalensis is not listed on the HMPC work program. As with other TCM-origin herbs (e.g., Astragalus), the EU regulatory framework has structural difficulty in accommodating non-European traditional medicines that do not meet the 30-year EU traditional use requirement.

Chinese Pharmacopoeia (2020 Edition)

• Official monograph as Huang Qin (黄芩). Scutellariae Radix is listed as an official drug in the Chinese Pharmacopoeia with the following requirements:
  • Minimum baicalin content: not less than 9.0% (90 mg/g) by HPLC assay
  • Source: dried root of Scutellaria baicalensis Georgi
  • First recorded in Shennong Bencaojing (The Classic of Herbal Medicine, ca. 200-250 AD)
• TCM functions: Clearing heat, eliminating dampness, purging fire, detoxification, hemostasis, and preventing miscarriage
• TCM properties: Bitter flavor, cold nature; enters the Lung, Gallbladder, Stomach, and Large Intestine meridians

Japanese Pharmacopoeia

• Listed as Ogon (黄芩). Scutellaria root is an official ingredient in multiple approved Kampo formulas covered by the Japanese national health insurance system, including:
  • Sho-saiko-to (小柴胡湯, Minor Bupleurum Decoction) — the most important formula containing Huang Qin
  • Dai-saiko-to (大柴胡湯, Major Bupleurum Decoction)
  • Saiko-keishi-to (柴胡桂枝湯, Bupleurum and Cinnamon Twig Decoction)
  • Saiko-ka-ryukotsu-borei-to (柴胡加竜骨牡蛎湯, Bupleurum plus Dragon Bone and Oyster Shell Decoction)
  • Ogi-kenchu-to (黄耆建中湯, Astragalus Middle-Strengthening Decoction)
  • San-o-sha-shin-to (三黄瀉心湯, Three Yellows Heart-Draining Decoction)

Korean Pharmacopoeia

• Listed. Used similarly to Chinese and Japanese pharmacopoeial standards.

Agreement/Disagreement

• Complete absence from European regulatory frameworks despite being one of the most pharmacologically studied plant-derived flavonoid sources in the world. The gap between the volume of scientific research on baicalin/baicalein (thousands of publications) and the absence of any Western regulatory recognition is striking. This reflects the structural limitations of EU herbal medicine regulation rather than any lack of scientific interest.

Conditions Treated

TCM Traditional Indications (Huang Qin)

• Damp-heat in the Lung: cough with thick yellow sputum, upper respiratory infections, pneumonia
• Damp-heat in the Stomach and Intestines: dysentery, diarrhea with fever, nausea
• Damp-heat jaundice: hepatitis, gallbladder inflammation
• Heat in the blood: epistaxis (nosebleeds), hematemesis, bloody stool, uterine bleeding
• Heat toxin: carbuncles, sores, swelling
• Restless fetus: threatened miscarriage due to heat (classical indication — Huang Qin is traditionally considered safe in pregnancy for this specific pattern, though modern Western guidance urges caution)
• Hypertension: traditionally used to “drain fire,” which correlates with blood pressure reduction

Modern/Western Research Indications

• Inflammatory conditions: Broad anti-inflammatory activity through multiple pathways; investigated for arthritis, inflammatory bowel disease, and neuroinflammation
• Respiratory infections: Antiviral activity against influenza A (H1N1, H3N2), respiratory syncytial virus (RSV), and SARS-CoV-2 (preclinical and in vitro)
• Allergic conditions: Regulation of Th1/Th2 balance; suppression of Th2-mediated allergic responses including allergic rhinitis and allergic asthma (preclinical)
• Liver protection: Hepatoprotective effects in preclinical models of drug-induced, alcohol-induced, and viral hepatitis; component of Sho-saiko-to used clinically for chronic hepatitis
• Cancer: Anti-proliferative and pro-apoptotic effects demonstrated in vitro against multiple cancer cell lines (hepatocellular carcinoma, lung, breast, colon); 12-LOX inhibition relevant to tumor growth inhibition; Sho-saiko-to studied for hepatocellular carcinoma prevention
• Neuroprotection: Baicalein crosses the blood-brain barrier; investigated for ischemic stroke, Parkinson’s disease, and Alzheimer’s disease (primarily preclinical)
• Autoimmune conditions: Modulation of Th17/Treg balance; studied in experimental autoimmune encephalomyelitis models

Mechanism of Action

Active Compounds

Pharmacokinetics of Baicalin/Baicalein

The absorption of baicalin and baicalein follows a complex pathway that depends on gut microbiota:

1. Baicalin (the dominant compound in the root) is poorly absorbed intact from the small intestine due to its glucuronide moiety
2. In the colon, bacterial beta-glucuronidase (particularly from E. coli) hydrolyzes baicalin to its aglycone baicalein
3. Baicalein is readily absorbed from the intestinal epithelium (Tmax approximately 10 minutes for pure baicalein vs. approximately 6-7 hours for baicalin)
4. Once absorbed, baicalein undergoes extensive first-pass glucuronidation by UDP-glucuronosyltransferase in the intestinal wall and liver, regenerating baicalin and baicalein-6-O-glucuronide in the systemic circulation
5. Enterohepatic recycling contributes to prolonged exposure and a secondary plasma peak
6. Absolute oral bioavailability of baicalin is low (approximately 2-3% as parent compound; approximately 28% when total baicalein equivalents are measured after enzymatic hydrolysis)

Anti-Inflammatory Mechanisms

1. NF-kB pathway inhibition: Baicalin suppresses the NF-kB signaling pathway through TLR4 receptor, inhibiting IkBa phosphorylation and degradation. This leads to reduced expression of iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6. This is the best-characterized anti-inflammatory mechanism. [PMID: 35573254]
2. “Dual inhibition” of COX and LOX: Baicalin and baicalein inhibit both cyclooxygenase (COX-2) and lipoxygenase (12-LOX, 15-LOX) enzymes, reducing production of pro-inflammatory eicosanoids including PGE2 and 12(S)-HETE. This dual inhibition distinguishes these flavones from conventional NSAIDs (COX-only) and offers broader anti-inflammatory coverage. [PMID: 24210837]
3. 12/15-Lipoxygenase inhibition: Baicalein is one of the most potent known natural 12/15-LOX inhibitors. This activity is relevant to cardioprotection (reduced myocardial ischemia/reperfusion injury via ERK1/2 and AKT pathway activation and inhibition of p38 MAPK, JNK1/2, and NF-kB/p65) and neuroprotection (post-stroke neuroinflammation). [PMID: 24297244]
4. MAPK pathway modulation: Inhibition of p38 MAPK and JNK signaling in macrophages and microglia
5. STAT3 pathway: Baicalein inhibits glycolysis via the STAT3/c-Myc pathway in activated microglia, attenuating neuroinflammation

Immunomodulatory Mechanisms

1. Th1/Th2 balance regulation: Baicalin, baicalein, and wogonin inhibit both Th1 cytokines (IL-6, IFN-gamma, TNF-alpha) and Th2 cytokines (IL-4, IL-13) in a concentration-dependent manner. The hexane fraction of Scutellaria suppresses Th2-mediated cytokines (IL-4, IL-5, IL-10, IL-13) while increasing Th1 cytokines (IFN-gamma, IL-12), suggesting a shift away from allergic Th2 dominance. [PMID: 28746342]
2. Treg cell modulation: Baicalin induces Foxp3 expression in a dose-dependent manner, promoting regulatory T cell (Treg) differentiation. In experimental autoimmune encephalomyelitis models, baicalin reduced Th17 cells by stimulating Treg cells and inhibiting IL-6 and IL-23. [PMID: 26616578]
3. Mast cell stabilization: Baicalein inhibits IL-1beta- and TNF-alpha-induced inflammatory cytokine production from human mast cells via NF-kB regulation. [PMID: 17999770]
4. Dendritic cell modulation: Influences dendritic cell maturation and antigen presentation
5. Broad immune cell effects: Baicalein, baicalin, wogonin, wogonoside, and oroxylin A act directly on lymphocytes, macrophages, mast cells, dendritic cells, monocytes, and neutrophils, inhibiting IL-1beta, IL-6, IL-8, and TNF-alpha production

Antiviral Mechanisms

1. Influenza A (H1N1, H3N2): Baicalin acts as a potent inducer of IFN-gamma in CD4+ and CD8+ T cells and NK cells; additionally inhibits neuraminidase activity (EC50 of 43.3 mcg/ml against H1N1 FM1/1/47 and 104.9 mcg/ml against H3N2 Beijing/32/92). Modulation of NS1-mediated cellular innate immune responses contributes to anti-influenza activity. [PMID: 25078390]
2. Respiratory syncytial virus (RSV): Baicalin blocks RSV infection and reduces inflammatory cell infiltration and lung injury in mouse models; regulates viral non-structural 1 (NS1) and matrix RNA expression. Wogonin also demonstrates anti-RSV activity. [PMC: 9148632]
3. SARS-CoV-2: Baicalein and baicalin inhibit SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and the 3CL protease in vitro. Baicalein inhibits mitochondrial oxidative phosphorylation (OXPHOS) through mPTP-dependent mechanisms in host cells, reducing viral replication. [PMID: 33801464; PMID: 37437351]

Clinical Evidence Summary

Overview

The clinical evidence for Scutellaria baicalensis is unusual in that the strongest data comes from multi-herb TCM formulas (particularly Xiao Chai Hu Tang/Sho-saiko-to) rather than standalone use of the herb. Standalone clinical trials are limited and mostly small. The preclinical pharmacology is exceptionally extensive.

Xiao Chai Hu Tang / Sho-saiko-to Formula Trials

Xiao Chai Hu Tang (Minor Bupleurum Decoction) is a classical TCM formula containing seven herbs: Bupleurum chinense (Chai Hu), Scutellaria baicalensis (Huang Qin, approximately 10% of formula), Pinellia ternata (Ban Xia), Panax ginseng (Ren Shen), Glycyrrhiza uralensis (Gan Cao), Ziziphus jujuba (Da Zao), and Zingiber officinale (Sheng Jiang). In Japanese Kampo medicine it is known as Sho-saiko-to (TJ-9).

Cochrane Review conclusions (2019): “The clinical effects of Xiao Chai Hu Tang formula for chronic hepatitis B remain unclear. Despite the wide use of the formula, there is a lack of data on all-cause mortality, serious adverse events, health-related quality of life, hepatitis B-related mortality, and hepatitis B-related morbidity.”

Standalone Scutellaria baicalensis Trials

HCC Prevention Meta-Analysis

A meta-analysis of seven RCTs (646 patients with hepatocellular carcinoma) found that Chinese herbal medicine preparations containing S. baicalensis as a main herb, combined with transcatheter arterial chemoembolization (TACE), significantly improved tumor objective response rate (RR = 1.57, 95% CI: 1.30-1.90, p < 0.00001). However, these were multi-herb formulations and the specific contribution of Scutellaria baicalensis cannot be isolated. [PMC: 10795786]

Evidence Quality Assessment

• Strongest evidence: Preclinical pharmacology of baicalin/baicalein (thousands of in vitro and animal studies; well-characterized molecular targets)
• Moderate evidence: Sho-saiko-to formula for chronic hepatitis (multiple controlled trials, but methodological limitations; one Cochrane review found only very low certainty evidence)
• Limited evidence: Standalone Scutellaria baicalensis clinical efficacy (very few RCTs; most clinical data is from multi-herb formulas where the specific contribution of Huang Qin cannot be determined)
• Key gap: The translation from exceptionally strong preclinical data to standalone clinical validation is the central challenge, similar to but even more pronounced than for Astragalus

Safety Profile

Hepatotoxicity: A Complex and Controversial Issue

Several reports and small case series have described acute liver injury with jaundice arising 1-3 months after starting dietary supplements containing Scutellaria baicalensis. However, this issue requires careful interpretation:

1. Contamination/adulteration concern: Phytochemical analyses have identified germander (Teucrium chamaedrys or T. canadense) as an adulterant in skullcap preparations. Germander contains hepatotoxic furan neoclerodane diterpenoids (teucrin A). Multiple cases initially attributed to skullcap were later linked to germander contamination. This is primarily a problem with American skullcap (Scutellaria lateriflora) products, but Chinese skullcap supplements may also be affected. [PMID: 19610368]
2. Confounding factors: In reported hepatotoxicity cases, patients were typically taking multiple supplements concurrently, at least one of which had an established association with liver injury.
3. Contradictory safety data: A study of 17 patients taking 1,335 mg Scutellaria baicalensis root daily for an average of 444 days showed no statistically significant changes in liver function tests and no clinical signs of hepatic dysfunction. [PMID: 31557595]
4. LiverTox assessment (NIH): The NCBI LiverTox database notes that there is “no convincing evidence” that Scutellaria baicalensis itself causes liver injury, and that the hepatotoxicity reports are likely attributable to germander contamination or other co-administered supplements.

Clinical recommendation: Use authenticated, quality-controlled Scutellaria baicalensis products from reputable suppliers. Monitor liver function if using long-term, particularly in patients with pre-existing liver disease.

Drug Interactions

Scutellaria baicalensis and its bioactive flavones affect the pharmacokinetic profile of multiple drugs through modulation of efflux pumps (P-glycoprotein) and cytochrome P450 enzymes. [PMID: 33711551]

Contraindications

• Pregnancy: Traditional TCM contraindication (Huang Qin is classified as “cold” and bitter; paradoxically, it is also traditionally used to “calm the fetus” in specific heat-pattern miscarriage, but this requires expert TCM differential diagnosis). Modern Western guidance: avoid during pregnancy due to insufficient safety data. Pregnancy category C.
• Spleen/stomach cold deficiency (TCM): The cold and bitter nature of Huang Qin can worsen digestive weakness characterized by cold-pattern loose stools, poor appetite, and abdominal distension.
• Known allergy to Lamiaceae family members
• Pre-existing liver disease: Use with caution and monitor liver function tests, given unresolved hepatotoxicity signal (likely related to adulteration but not definitively excluded)
• Patients taking narrow therapeutic index drugs: Warfarin, cyclosporine, digoxin, phenytoin — due to pharmacokinetic interactions

Side Effects

• Gastrointestinal: Nausea, diarrhea, stomach discomfort (related to the cold, bitter nature of the herb in TCM terms)
• Elevated triglycerides: Possibly related to baicalein ingestion in healthy subjects (observed in safety study)
• Elevated high-sensitivity CRP: Possibly related to baicalein tablet ingestion (clinical significance uncertain)
• Overall: Generally well tolerated at traditional TCM doses (3-15 g dried root in decoction)

Pregnancy/Lactation

• Pregnancy: Contraindicated by modern Western standards due to insufficient human safety data. In TCM, Huang Qin has a complex relationship with pregnancy: it is traditionally used to prevent miscarriage in heat-pattern presentations, but is contraindicated in cold-deficiency patterns. This nuanced use requires expert TCM diagnosis and is not translatable to general supplement use.
• Lactation: Insufficient data. Not recommended.

Clinical Dosage

Dried Root — Traditional TCM Decoction

• Standard dose: 3-9 g dried root per day in decoction (Chinese Pharmacopoeia recommended range)
• Higher doses: Up to 15 g in some TCM protocols for acute heat conditions
• Preparation: Typically sliced and simmered in water for 20-30 minutes as part of a multi-herb formula. The root may be used raw (Sheng Huang Qin, for clearing heat), wine-fried (Jiu Huang Qin, for clearing upper body heat), or charcoal-fried (Huang Qin Tan, for stopping bleeding).

Standardized Extracts

• Root extract: 250-500 mg, 1-3 times daily
• Standardization: Typically standardized to 85% baicalin for concentrated extract products; some products standardized to total flavonoid content
• Baicalein isolate: 100-800 mg daily (used in some clinical studies and supplements)

Key Multi-Herb Formulas (Standardized)

• Sho-saiko-to (TJ-9): 7.5 g granule extract daily (Japanese standard Kampo dose), containing approximately 3 g Scutellaria root equivalent. This is the dose used in the Oka 1995 hepatocellular carcinoma prevention trial.
• Xiao Chai Hu Tang decoction: Variable, typically 9 g Huang Qin per formula dose in classical proportions

Quality Considerations

• Products should meet the Chinese Pharmacopoeia standard of minimum 9.0% baicalin content
• Authentication is critical to avoid adulteration with germander (Teucrium spp.) or substitution with other Scutellaria species
• HPLC verification of baicalin, baicalein, and wogonin content is the analytical standard
• GMP-certified suppliers with certificate of analysis (CoA) are recommended

Duration

• Acute use: 5-14 days for respiratory infections and acute inflammatory conditions
• Chronic use: Up to several months in TCM practice (traditionally used long-term as part of formulas); the 444-day safety study provides some reassurance for extended use at moderate doses
• Kampo/TCM formula use: Often used for months to years under practitioner supervision for chronic hepatitis and other chronic conditions

Sources

• Zhao T et al. “Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology.” J Pharm Pharmacol. 2019;71(9):1353-1369. (PMID: 31236960)
• Zhao Q et al. “Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants.” Sci Bull. 2016;61(18):1391-1398. (PMC5031759)
• Li HB et al. “A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis.” Pharm Biol. 2019;57(1):22-32. (PMC6292351)
• Fang J et al. “An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways.” Front Pharmacol. 2022;13:913175. (PMID: 35573254; PMC9118284)
• Li L et al. “The Pharmacological Efficacy of Baicalin in Inflammatory Diseases.” Curr Drug Targets. 2023;24(7):587-599. (PMC10253382)
• Oka H et al. “Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9).” Cancer. 1995;76(5):743-749. (PMID: 8625175)
• Tajiri H et al. “Effect of sho-saiko-to on HBeAg clearance in children with chronic hepatitis B.” Am J Chin Med. 1991;19(2):121-129. (PMID: 1816724)
• Kong DZ et al. “Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.” Cochrane Database Syst Rev. 2019;11:CD013090. (PMID: 31697415)
• Dinda B et al. “An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin.” Eur J Med Chem. 2023;258:115629. (PMID: 37437351)
• Nayak MK et al. “Antiviral activity of baicalin against influenza virus H1N1-pdm09 and its inhibition of neuraminidase.” Arch Virol. 2014;159(8):2115-2127. (PMID: 25078390)
• Moghaddam E et al. “Baicalin, a metabolite of baicalein with antiviral activity against dengue virus.” Sci Rep. 2014;4:5452. (PMC: 4068332)
• Deng YF et al. “Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs.” Biomed Pharmacother. 2021;138:111509. (PMID: 33711551)
• Yimam M et al. “The effect of supplementation with Scutellaria baicalensis on hepatic function.” J Altern Complement Med. 2019;25(12):1214-1220. (PMID: 31557595)
• NIH LiverTox: “Skullcap.” National Institute of Diabetes and Digestive and Kidney Diseases (https://www.ncbi.nlm.nih.gov/books/NBK548757/)
• Liu C et al. “Baicalein inhibits IL-1beta- and TNF-alpha-induced inflammatory cytokine production from human mast cells via regulation of the NF-kappaB pathway.” Clin Mol Allergy. 2007;5:5. (PMID: 17999770; PMC2206049)
• Cheng CS et al. “Scutellaria baicalensis and cancer treatment.” Am J Chin Med. 2018;46(1):33-68.
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. 2020 Edition. China Medical Science Press.
• Lee JS et al. “Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma.” Hepatol Res. 2011;41(9):825-837.

Connections

• Astragalus: Both are foundational TCM immune-support herbs; Astragalus (Huang Qi) “tonifies Qi” while Baikal Skullcap (Huang Qin) “clears heat” — they are frequently combined in formulas for immune regulation and represent complementary therapeutic strategies (warming/tonifying vs. cooling/clearing)
• Andrographis: Both possess strong anti-inflammatory and antiviral properties with NF-kB inhibition as a shared mechanism; both lack European regulatory recognition despite substantial pharmacological evidence; Andrographis has better standalone RCT data (Kan Jang trials)
• Cat’s Claw: Both are immunomodulatory herbs with NF-kB pathway inhibition; Cat’s Claw from South American tradition vs. Baikal Skullcap from TCM tradition
• Reishi: Both are major East Asian medicinal products used for immune modulation and liver support; Reishi acts primarily through polysaccharides (beta-glucans) while Baikal Skullcap acts through flavones
• Berberine: Both are bitter, cold TCM substances used to “clear heat”; frequently combined in classical formulas (e.g., San Huang formulas containing both Huang Qin and Huang Lian/Huang Bai); complementary anti-inflammatory mechanisms